BCAB
BioAtla, Inc.
Key Financials
Operating Income
$-59305000
↑ 19.8%
Revenue
$300000
0.0%
Net Income
$-59607000
↑ 14.6%
EPS (Diluted)
$-1.01
↑ 29.9%
Cash & Equivalents
$7.1M
↓ 85.5%
Shareholders' Equity
$-36189000.00
↓ 353.7%
Total Liabilities
$50.0M
↑ 31.1%
Total Assets
$13.8M
↓ 73.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/2/2026 | View on SEC |
| S-8 | 3/31/2026 | View on SEC |
| 10-K | 3/31/2026 | View on SEC |
| 8-K | 3/31/2026 | View on SEC |
| 8-K | 3/23/2026 | View on SEC |
| 424B2 | 3/20/2026 | View on SEC |
| 424B2 | 3/13/2026 | View on SEC |
| 4 | 3/12/2026 | View on SEC |
| 4 | 3/12/2026 | View on SEC |
| 4 | 3/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BCAB |
| Company Name | BioAtla, Inc. |
| CIK | 1826892 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-558-0708 |